Stereotaxis (NYSE: STXS) shares were virtually unchanged Wednesday. The St. Louis-based company, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its portfolio of digital and robotic technologies will be featured at Heart Rhythm Society’s HRX conference, taking place next weekend in Atlanta.
Pioneered by the Heart Rhythm Society, HRX brings together clinicians, engineers, and entrepreneurs to explore advances in connectivity, artificial intelligence and automation in cardiovascular medicine.
Synchrony, Stereotaxis’ integrated lab display, and SynX, its cloud-based connectivity platform will be among the technologies featured at the conference, along with expert discussions and hands-on experiences focused on the future of cardiovascular care.
CEO David Fischel will join a panel of clinical experts on the main stage to discuss the feasibility and potential value of autonomous technologies in the EP lab.
The session, “Autonomous and Assistive EP Procedural Systems,” will explore how emerging technologies could improve procedure workflows and expand clinical capabilities. It will take place September 19, will be moderated by Dr. Peter Weiss, and will include physician panelists Dr. Jim Cheung and Dr. Jennifer Silva.
Stereotaxis has incorporated initial automation capabilities into its robotic systems and is developing enhanced automation capabilities for catheter and interventional device navigation in Electrophysiology, Interventional Cardiology, and Neurointerventions.
STXS shares retreated a penny to $1.31.
